Does the media favor SNDX or EIKN?

In the previous week, Syndax Pharmaceuticals had 17 more articles in the media than Eikon Therapeutics. MarketBeat recorded 19 mentions for Syndax Pharmaceuticals and 2 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.43 beat Syndax Pharmaceuticals' score of -0.06 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 6 Negative mention(s) 1 Very Negative mention(s) Neutral Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STOK or EIKN?

In the previous week, Stoke Therapeutics had 4 more articles in the media than Eikon Therapeutics. MarketBeat recorded 6 mentions for Stoke Therapeutics and 2 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.43 beat Stoke Therapeutics' score of 0.54 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor QURE or EIKN?

In the previous week, uniQure and uniQure both had 2 articles in the media. Eikon Therapeutics' average media sentiment score of 1.43 beat uniQure's score of 0.82 indicating that Eikon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, EIKN or AAPG?

Ascentage Pharma Group International has higher revenue and earnings than Eikon Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A -$324.25M -$4.09 N/A Ascentage Pharma Group International $82.10M 17.13 -$177.71M N/A N/A

Is EIKN or AAPG more profitable?

Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Ascentage Pharma Group International N/A N/A N/A

Eikon Therapeutics (EIKN) Competitors

$6.72 -0.54 (-7.44%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$6.77 +0.05 (+0.68%)

As of 08:44 AM Eastern

Compare

EIKN vs. SNDX, STOK, IMCR, QURE, and AAPG

Should you buy Eikon Therapeutics stock or one of its competitors? Eikon Therapeutics's main competitors and comparable companies include Syndax Pharmaceuticals (SNDX), Stoke Therapeutics (STOK), Immunocore (IMCR), uniQure (QURE), and Ascentage Pharma Group International (AAPG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eikon Therapeutics compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Syndax Pharmaceuticals currently has a consensus price target of $41.80, indicating a potential upside of 199.64%. Eikon Therapeutics has a consensus price target of $25.00, indicating a potential upside of 272.02%. Given Eikon Therapeutics' higher probable upside, analysts clearly believe Eikon Therapeutics is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Syndax Pharmaceuticals has higher revenue and earnings than Eikon Therapeutics. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	7.17	-$285.42M	-$2.51	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

Eikon Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Eikon Therapeutics' return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Eikon Therapeutics	N/A	N/A	N/A

In the previous week, Syndax Pharmaceuticals had 17 more articles in the media than Eikon Therapeutics. MarketBeat recorded 19 mentions for Syndax Pharmaceuticals and 2 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.43 beat Syndax Pharmaceuticals' score of -0.06 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Syndax Pharmaceuticals and Eikon Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Eikon Therapeutics compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Stoke Therapeutics presently has a consensus price target of $44.25, indicating a potential upside of 96.67%. Eikon Therapeutics has a consensus price target of $25.00, indicating a potential upside of 272.02%. Given Eikon Therapeutics' higher probable upside, analysts clearly believe Eikon Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Stoke Therapeutics had 4 more articles in the media than Eikon Therapeutics. MarketBeat recorded 6 mentions for Stoke Therapeutics and 2 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.43 beat Stoke Therapeutics' score of 0.54 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Eikon Therapeutics' return on equity of 0.00% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Eikon Therapeutics	N/A	N/A	N/A

Stoke Therapeutics has higher revenue and earnings than Eikon Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	7.87	-$6.89M	-$3.34	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

Summary

Stoke Therapeutics and Eikon Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Eikon Therapeutics compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

In the previous week, Eikon Therapeutics had 1 more articles in the media than Immunocore. MarketBeat recorded 2 mentions for Eikon Therapeutics and 1 mentions for Immunocore. Eikon Therapeutics' average media sentiment score of 1.43 beat Immunocore's score of 0.81 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Immunocore	Positive
Eikon Therapeutics	Positive

Eikon Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Eikon Therapeutics' return on equity of 0.00% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Eikon Therapeutics	N/A	N/A	N/A

Immunocore currently has a consensus target price of $56.38, indicating a potential upside of 102.64%. Eikon Therapeutics has a consensus target price of $25.00, indicating a potential upside of 272.02%. Given Eikon Therapeutics' higher possible upside, analysts plainly believe Eikon Therapeutics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

84.5% of Immunocore shares are held by institutional investors. 10.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Immunocore has higher revenue and earnings than Eikon Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.58	-$35.51M	-$0.37	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

Summary

Immunocore beats Eikon Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Eikon Therapeutics compare to uniQure?

uniQure (NASDAQ:QURE) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Eikon Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. Eikon Therapeutics' return on equity of 0.00% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Eikon Therapeutics	N/A	N/A	N/A

uniQure currently has a consensus target price of $53.73, suggesting a potential upside of 152.48%. Eikon Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 272.02%. Given Eikon Therapeutics' higher probable upside, analysts clearly believe Eikon Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.75
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

uniQure has higher revenue and earnings than Eikon Therapeutics. uniQure is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	91.69	-$198.97M	-$4.01	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A

In the previous week, uniQure and uniQure both had 2 articles in the media. Eikon Therapeutics' average media sentiment score of 1.43 beat uniQure's score of 0.82 indicating that Eikon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of uniQure shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

uniQure beats Eikon Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Eikon Therapeutics compare to Ascentage Pharma Group International?

Eikon Therapeutics (NASDAQ:EIKN) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Ascentage Pharma Group International has higher revenue and earnings than Eikon Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A
Ascentage Pharma Group International	$82.10M	17.13	-$177.71M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Ascentage Pharma Group International	N/A	N/A	N/A

In the previous week, Ascentage Pharma Group International had 7 more articles in the media than Eikon Therapeutics. MarketBeat recorded 9 mentions for Ascentage Pharma Group International and 2 mentions for Eikon Therapeutics. Eikon Therapeutics' average media sentiment score of 1.43 beat Ascentage Pharma Group International's score of 0.31 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascentage Pharma Group International	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eikon Therapeutics currently has a consensus price target of $25.00, suggesting a potential upside of 272.02%. Ascentage Pharma Group International has a consensus price target of $43.67, suggesting a potential upside of 189.95%. Given Eikon Therapeutics' higher probable upside, equities research analysts plainly believe Eikon Therapeutics is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.15

Summary

Ascentage Pharma Group International beats Eikon Therapeutics on 6 of the 8 factors compared between the two stocks.

Get Eikon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EIKN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EIKN vs. The Competition

Export

Metric	Eikon Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$393.24M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	11.31	206.66	19.94
Price / Sales	N/A	1,148.46	562.21	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	N/A	17.08	10.75	6.03
Net Income	-$324.25M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-10.88%	-4.43%	-2.91%	-2.34%
1 Month Performance	-28.21%	-12.48%	-7.38%	-5.31%
1 Year Performance	N/A	7.60%	2.96%	-2.94%

Eikon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EIKN Eikon Therapeutics	3.295 of 5 stars	$6.72 -7.4%	$25.00 +272.0%	N/A	$393.24M	N/A	N/A	384	News Coverage Positive News
SNDX Syndax Pharmaceuticals	2.7056 of 5 stars	$17.79 -0.2%	$41.80 +135.0%	-8.2%	$1.58B	$172.35M	N/A	298	Trending News Analyst Forecast
STOK Stoke Therapeutics	2.5574 of 5 stars	$24.23 -4.3%	$44.25 +82.6%	-25.8%	$1.57B	$27.59M	N/A	170
IMCR Immunocore	3.3085 of 5 stars	$30.15 +1.9%	$56.38 +87.0%	-14.0%	$1.55B	$430.78M	N/A	524
QURE uniQure	3.9137 of 5 stars	$22.06 -3.3%	$53.73 +143.6%	-65.7%	$1.54B	$16.10M	N/A	221

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EIKN) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eikon Therapeutics (EIKN) Competitors

EIKN vs. SNDX, STOK, IMCR, QURE, and AAPG

How does Eikon Therapeutics compare to Syndax Pharmaceuticals?

Summary

How does Eikon Therapeutics compare to Stoke Therapeutics?

Summary

How does Eikon Therapeutics compare to Immunocore?

Summary

How does Eikon Therapeutics compare to uniQure?

Summary

How does Eikon Therapeutics compare to Ascentage Pharma Group International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

Eikon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eikon Therapeutics (EIKN) Competitors

EIKN vs. SNDX, STOK, IMCR, QURE, and AAPG

How does Eikon Therapeutics compare to Syndax Pharmaceuticals?

Do analysts recommend SNDX or EIKN?

Which has preferable earnings & valuation, SNDX or EIKN?

Is SNDX or EIKN more profitable?

Does the media favor SNDX or EIKN?

Summary

How does Eikon Therapeutics compare to Stoke Therapeutics?

Do analysts prefer STOK or EIKN?

Does the media favor STOK or EIKN?

Is STOK or EIKN more profitable?

Which has preferable valuation & earnings, STOK or EIKN?

Summary

How does Eikon Therapeutics compare to Immunocore?

Does the media favor IMCR or EIKN?

Is IMCR or EIKN more profitable?

Do analysts prefer IMCR or EIKN?

Do insiders & institutionals believe in IMCR or EIKN?

Which has better valuation & earnings, IMCR or EIKN?

Summary

How does Eikon Therapeutics compare to uniQure?

Is QURE or EIKN more profitable?

Do analysts prefer QURE or EIKN?

Which has preferable earnings & valuation, QURE or EIKN?

Does the media favor QURE or EIKN?

Do insiders & institutionals have more ownership in QURE or EIKN?

Summary

How does Eikon Therapeutics compare to Ascentage Pharma Group International?

Which has stronger valuation and earnings, EIKN or AAPG?

Is EIKN or AAPG more profitable?

Does the media refer more to EIKN or AAPG?

Do analysts prefer EIKN or AAPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EIKN vs. The Competition

Eikon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools